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Objective. To clarify the impact of H221Y mutation on drug resistance to NVP. Methods. 646bp HIV-1 pol gene fragments
(from 592 to 1237 nucleotide) with diﬀerent NNRTIs mutation proﬁles from AIDS patients receiving antiretroviral therapy
containing NVP regimens were introduced into pNL4-3 backbone plasmid. H221Y and (or) Y181C mutations were reverted
to wild type amino acids by site-directed mutagenesis, then strains containing various mutation patterns were packaged.
Phenotypic drug resistance was analyzed on TZM-bl cells. Results. 12 strains containing diﬀerent drug-resistant mutation
proﬁles were constructed, including the K101Q series (K101Q/Y181C/H221Y, K101Q/Y181C, K101Q/H221Y, and K101Q), the
V179D series (V179D/Y181C/H221Y, V179D/Y181C, V179D/H221Y, and V179D), and the K103N series (K103N/Y181C/H221Y,
K103N/Y181C, K103N/H221Y, K103N). For strains containing the mutation proﬁles (K101Q/Y181C, K101Q, V179D/Y181C,
V179D, K103N/Y181C, and K103N), the presence of H221Y reduced NVP susceptibility by 2.1 ± 0.5t o3 .6 ± 0.5 fold. To the
mutation proﬁles K101Q/H221Y, K101Q, V179D/H221Y, V179D, K103N/H221Y, and K103N, the presence of Y181C reduced
NVP susceptibility by 41.9 ± 8.4 to 1297.0 ± 289.1 fold. For the strains containing K101Q, V179D, and K103N, the presence of
Y181C/H221Y combination decreased NVP susceptibility by 100.6 ± 32.5 to 3444.6 ± 834.5 fold. Conclusion. On the bases of
various NNRTIs mutation proﬁles, Y181C remarkably improved the IC50 to NVP, although H221Ymutation alone just increases
2.1 ∼3.6-foldresistancetoNVP,themutationcouldimprove100.6 ∼3444.6-foldresistancetoNVPwhenitcopresentwithY181C,
the phenotypic drug resistance fold was improved extremely. For strains containing the mutation proﬁles (K101Q/Y181C, K101Q,
V179D/Y181C, V179D, K103N/Y181C, and K103N), the presence of H221Y reduced NVP susceptibility by 2.1 ± 0.5t o3 .6 ± 0.5
fold.
1.Introduction
The nonnucleoside reverse transcriptase inhibitors (NNR-
TIs) are small molecules which can bind to a nonactive
hydrophobic site pocket close to the catalytic domain of RT
(termed NNRTI-binding pocket). The binding of NNRTIs to
RT could alter the structure of RT and block the polymerase
activity of RT. As the results, the replications of HIV-1 were
inhibited. However, despite their high eﬃciencies and low
toxicities, the use of NNRTIs is hampered owing to the rapid
selection of drug-resistant HIV-1 strains [1, 2]. Therefore, a
deeper understanding of resistance is necessary in order to
eﬀectively prevent and manage HIV-1 drug resistance.
Almost all NNRTIs-related mutations were identiﬁed
with their location in binding pocket or near the pocket [3].
These mutations can change the size, shape, and polarity of
the pocket and aﬀect the binding of NNRTIs accordingly
[4]. There are four types of NNRTIs-resistant mutations: (1)
Primary mutation: these mutations emerge earliest during
therapy and cause high-level resistance to one or more NNR-
TIs, including K103N/S, Y181C/I/V, V106A/M, Y188L/C/H,
and G190A/S/E. All these mutations can lead to high-level
resistance to NVP. (2) Secondary mutation: these mutations
usually appear with primary mutations but occasionally
occur by themselves. Several of these mutations, particularly
K101E/P and M230L, have been associated with signiﬁcant2 AIDS Research and Treatment
resistance to multiple NNRTIs. (3) Minor nonpolymorphic
mutation and accessory mutation: these mutations emerge
alone or couple with other NNRTIs-resistant mutations and
confer decreasing NNRTIs susceptibility persistently. This
type of mutation consists of A98G, K101Q, V108I, and
V179D/E. These mutations, such as K101Q and V179I,
often occur with other primary mutations. In previous
study, in contrast with NRTIs resistance, a single NNRTIs
mutation in HIV-1 RT can lead to high-level resistance to
multi-NNRTIs (including efavirenz and nevirapine). So in
the past, researchers seldom pay attention to the NNRTIs-
resistant proﬁles resulting from therapy failure because a
single NNRTI treatment failure always means the second
NNRTI therapy failure [5–7].
H221YwasrecentlyfoundasanNNRTIsmutationwhich
confers resistance to NVP. Our previous study showed that
the virus carrying K103N/Y181C/H221Y mutation combi-
nation could replicate stably in vitro in absence of drugs [8].
However, the impact of H221Y on NNRTI susceptibility has
beenpoorlycharacterized,andtheinteractionofH221Ywith
other mutations is yet indistinct. The objective of this study
is to clarify the impact of H221Y by itself and combination
with other mutations on drug resistance to NVP.
2.MaterialsandMethods
Selection of Plasma Samples. Plasma samples were collected
from 3 AIDS patients in clinical cohort receiving antiretro-
viral therapy [nevirapine (NVP) + zidovudine (AZT) +
didanosine (ddI)]. All patients have written informed con-
sent. Genotype-resistant results of these patients showed all
samples contained three NNRTIs mutations (Y181C/H221Y
plus another mutation) which conferred resistance to NVP.
Viral RNA Extraction and One-Step RT PCR. RNA was
extracted from 200μL plasma using High Pure Viral RNA
Kit (Roche Corp.) following the protocol provided with kits.
HIV-1 pol protease and reverse transcriptase genes were
obtained by one-step RT PCR.
Cloning of the HIV-1 Protease and RT (Reverse Transcriptase)
Gene PCR Products. The PCR products were cleaned by
Wizard SV Gel and PCR Clean-Up System (Promega Corp.)
and ligated with PMD18-T Vector (TaKaRa Biotechnology
Co., Ltd.), then transformed into E. coli DH5α.
Selection of Clones with 3 Diﬀerent Mutation Proﬁles to
NVP. Several clones from each transformation were se-
quenced, and 3 clones containing 3 diﬀerent NNRTIs
mutation proﬁles, including K101Q/Y181C/H221Y, V179D/
Y181C/H221Y, and K103N/Y181C/H221Y, were selected.
Construction of 12 Clones with Diﬀerent NVP-Resistant Mu-
tation Proﬁles Using Site-Directed Mutagenesis. Three frag-
m e n t sw e r ec o n s t r u c t e dt o c o n v e r t m u t a n t R T 2 2 1 ( Y ) t o
wild-type (H) or (/and) convert mutant RT 181 (C) to wild-
type (Y) by site-directed mutant-genesis kit (TaKaRa Mutan
BEST kit, TaKaRa Biotechnology Co. Ltd.) with mutagenic
primers: 221Y→H, 5 -ACAAAAAACATCAGAAA GAAC-
CTCCAT-3  (H221-F (C-6/P-110)), 5 -ACAAAAAACATC-
AGAAAGAACCCCC-3  (H221-F(P-22)), 5 -CTGGTGTGG-
TAAATCCCCACCT-3  (H221-R(C-6-2)),5 -CTGGTGTGT-
AAAACCCCCACCTTAAC-3  (H221-R (P-22)), and 5 -
CTGGTGT GTAAAATCCCCACCTCAA-3  (H221-R(P-
110)); 181C→Y, 5 -ATAGTTATC TATC AATACATGGATG-
ATTTGTATGT-3  (Y181-F(C-6/P-110)829), 5 -ATGGAA-
ATCT ATCAATACATGGATGATTTGT-3  (Y181-F(P-22-6)
829), 5 -GTCTGGATTTTGTT TTCTAAAAGGCTC-3 
(Y181-R 828). Diﬀerent mutation proﬁles were created
including K101Q/Y181C/ H221Y, K101Q/Y181C, K101Q/
H221Y, K101Q, V179D/Y181C/ H221Y, V179D/Y181C,
V179D/H221Y, V179D, K103N/ Y181C/H221Y, K103N/
Y181C, K103N/H221Y, and K103N. All of mutations
were conﬁrmed by sequencing with primers: 5 -GCCATA-
AAGAAAAAARACAGTACTARA-3  (Mut-F 481) and 5 -
TCATTCTTGCATAYTTTCCTGT TTT-3  (Mut-R 1369).
Insertion of the RT Fragments into the Backbone pNL4-3
Vector. Two restriction sites (Sbf/ and Age/)w e r ec r e a t e di n
the12fragmentswithdiﬀerentmutationproﬁles.The646bp
fragments were digested with Sbf/ and Age/,p u r i ﬁ e dw i t h
Wizard SV Gel and PCR Clean-Up System (Promega Corp.),
and inserted into backbone pNL4-3 vector which had been
removed the corresponding fragments.
PreparationofPlasmidDNA. Themutationsintroducedinto
pNL4-3 vectors were conﬁrmed by sequencing primers:
5 -GCCATAAAGAAAAAAGACAGTACTAAA-3  (NL + aim-
F481) and 5 -CCTTCATTCTTGCATATTTTCCT-3  (NL +
aim-R 1372) before being prepared by QIAGEN Plasmid
Midi Kit (25) (QIAGEN Corp.).
Cells and Media. The 293T and the TZM-bl cell lines were
presentedbythenucleicacidvaccinelaboratoryofUniversity
of Massachusetts Medical School and were maintained in
DMEM (Invitrogen, Corp.) medium containing 10% fetal
bovine serum.
Transfections, Infections, and NVP Susceptibility Assays. The
ligated pNL4-3 plasmids were transfected into 293T cells
by using Lipofectamine 2000 (Invitrogen, Corp.). TCID50
of the virus culture supernatant and IC50st oN V Pw e r e
detected by using TZM-bl cells. The IC50s were determined
by concentration-response curves of the log10 NVP concen-
tration versus percent inhibition of virus.
3. Results
Construction 12 HIV-1 Virus Containing Diﬀerent Mutation
Proﬁles. These viruses were named 101Q-1, 101Q-2, 101Q-
3, 101Q-4, 179D-1, 179D-2, 179D-3, 179D-4, 103N-1,
103N-2, 103N-3, and 103N-4; the mutation patterns
they contained were K101Q/Y181C/H221Y, K101Q/Y181C,
K101Q/H221Y, K101Q, V179D/Y181C/ H221Y, V179D/
Y181C, V179D/H221Y, V179D, K103N/ Y181C/H221Y,AIDS Research and Treatment 3
Table 1: The greatest initial NVP concentrations of every virus, IC50 (μM) of every virus and the increased NVP resistance compared to
pNL4-3.
Virus no. Mutation patterns Greatest concentration
of NVP (μM) IC50 (μM) Median fold of IC50 increased
compared to pNL4-3 (±S.D.)
101Q-1 K101Q/Y181C/H221Y 1000 108.2 ±1.9 3740.8 (±314.1)
101Q-2 K101Q/Y181C 200 47.8 ±18.1 1490.9 (±354.4)
101Q-3 K101Q/H221Y 2 0.14 ±0.05 4.4 (±1.2)
101Q-4 K101Q 0.5 0.04 ±0.01 1.2 (±0.2)
179D-1 V179D/Y181C/H221Y 500 162.6 ±47.5 5090.6 (±744.6)
179D-2 V179D/Y181C 500 45.0 ±12.8 1413.0 (±269.8)
179D-3 V179D/H221Y 5 0.4 ±0.0 13.4 (±1.9)
179D-4 V179D 1.25 0.1 ±0.04 . 6 ( ±1.3)
103N-1 K103N/Y181C/H221Y 1000 191.1 ±91.4 5859.3 (±1648.2)
103N-2 K103N/Y181C 1000 89.2 ±22.7 2802.4 (±124.1)
103N-3 K103N/H221Y 50 4.4 ±0.9 139.2 (±8.2)
103N-4 K103N 25 2.0 ±0.4 63.8 (±3.1)
Con-1 1 0.03 ±0.01
K103N/Y181C, K103N/H221Y, and K103N. As the control
virus, Con-1 was pNL4-3 without any drug-resistant muta-
tions. The virus name and corresponding drug resistance
mutation proﬁles were indicated at Table 1.
IC50s of 13 Virus. Firstly, we measured the TCID50so f
recombinant virus with TZM-bl cells. TCID50so fv i r u s
101Q-1, 101Q-2, 101Q-3, 101Q-4, 179D-1, 179D-2, 179D-
3, 179D-4, 103N-1, 103N-2, 103N-3, 103N-4, and Con-1
were 10687, 6250, 18275, 6250, 156250, 21555, 45305, 31250,
31250, 18275, 13975, and 4780 per milliliter, respectively. To
determine the IC50s of NVP versus every virus, we identiﬁed
the concentration range of high and low inhibition and
ensured that the greatest concentration can inhibit 95%
viruses at least, and the lowest concentration can inhibit
10 ∼ 15%. NVP concentrations of all viruses were diluted
double successivelyexcept virus Con-1 triplicate successively.
The greatest concentrations of every virus were showed in
Table 1.
Three independent experiments were performed in trip-
licate. The curves of percent inhibition of virus to log10 NVP
concentration were created and showed in Figures 1, 2 and
3.I C 50s of 13 viruses were separately 108.2 ± 1.9μM, 47.8 ±
18.1μM, 0.14 ± 0.05μM, 0.04 ± 0.01μM, 162.6 ± 47.5μM,
45.0 ±12.8μM, 0.4 ±0.0μM, 0.1 ±0.0μM, 191.1 ±91.4μM,
89.2±22.7μM,4.4±0.9μM,2.0±0.4μM,and0.03±0.01μM
(Table 1).
Susceptibility Reduction of Various Mutation Patterns
Compared to pNL4-3. Compared to pNL4-3, the resistance
values (folds of IC50 increased) derived from viruses car-
rying diﬀerent mutation proﬁles such as K101Q/ Y181C/
H221Y, K101Q/Y181C, K101Q/H221Y, K101Q, V179D/
Y181C/H221Y, V179D/Y181C, V179D/H221Y, V179D,
K103N/Y181C/H221Y, K103N/Y181C, K103N/ H221Y, and
Table 2: Contribution of H221Y, Y181C, H221Y/Y181C to an
increased NVP resistance based on various mutation proﬁles.
Aimed mutation Base mutation
proﬁle
Increased fold of IC50
(±S.D.)
H221Y K101Q/Y181C 2.2 (±0.9)
H221Y K101Q 3.2 (±0.3)
H221Y V179D/Y181C 3.6 (±0.5)
H221Y V179D 3.0 (±0.4)
H221Y K103N/Y181C 2.1 (±0.5)
H221Y K103N 2.2 (±0.1)
Y181C K101Q/H221Y 759.1 (±41.9)
Y181C K101Q 1297.0 (±289.1)
Y181C V179D/H221Y 390.0 (±101.6)
Y181C V179D 312.5 (±45.3)
Y181C K103N/H221Y 41.9 (±8.4)
Y181C K103N 47.9 (±4.2)
Y181C/H221Y K101Q 3444.6 (±834.5)
Y181C/H221Y V179D 1132.6 (±180.4)
Y181C/H221Y K103N 100.6 (±32.5)
K103N were 3740.8 ± 314.1, 1490.9 ± 354.4, 4.4 ± 1.2,
1.2±0.2, 5090.6±744.6, 1413.0±269.8, 13.4±1.9, 4.6±1.3,
5859.3 ± 1648.2, 2802.4 ± 124.1, 139.2 ± 8.2, and 63.8 ± 3.1
folds, respectively (Table 1).
Association of H221Y with an Increased NVP IC50 Based on
Various Mutation Proﬁles. As for diﬀerent mutation patterns
including K101Q/Y181C, K101Q, V179D/Y181C, V179D,
K103N/Y181C and K103N, H221Y conferred NVP IC50
increasedfolds2.2±0.9,3.2±0.3,3.6±0.5,3.0±0.4,2.1±0.5,
and 2.2 ±0.1, respectively (Table 2).4 AIDS Research and Treatment
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Figure 1: The curves of percent inhibition of virus 101Q-1∼101Q-4 to log10 NVP concentration.
Table 3: The complete set of diﬀerences from consensus B (from 99 to 313 AA in pol region).
Virus Position of AA in pol region
101 103 135 162 178 179 181 200 203 207 215 221 228 272 277 278 292 293 297 311 312
Consensus B K KISIVY TEQTHLAKQVIEKE
101Q-1 Q —RC——C A———Y ——R E —————
101Q-2 Q —RC——C A——————R E —————
101Q-3 Q —R C———A——— Y ——R E —————
101Q-4 Q —R C———A——————R E —————
179D-1 — — V C M D C AGEYYR—R E I V———
179D-2 — — V C M D C AGEY —R—R E I V— — —
179D-3 — — V C M D — A G E YYR—R E I V———
179D-4 — — V C M D — A G E Y–R—R E I V———
103N-1 — N V C — — C A——YY —SRE— —KSK
103N-2 — N V C — — C A——Y —— S R E ——K S K
103N-3 — N V C — — — A — — YY —SRE— —KSK
103N-4 — N V C — — — A — — Y —— S R E ——K S K
Association of Y181C with an Increased NVP IC50 Based on
Various Mutation Proﬁles. In relation to various mutation
proﬁles such as K101Q/H221Y, K101Q, V179D/H221Y,
V179D, K103N/H221Y, and K103N, Y181C mutation
increased folds of NVP and IC50s were 759.1±41.9, 1297.0±
289.1, 390.0±101.6, 312.5±45.3, 41.9±8.4, and 47.9±4.2,
respectively (Table 2).
Association of Y181C/H221Y with an Increased NVP IC50
Based on Various Mutation Proﬁles. Concerning K101Q,AIDS Research and Treatment 5
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Figure 2: The curves of percent inhibition of virus 179D-1∼179D-4 to log10 NVP concentration.
V179D, and K103N, Y181C/H221Y mutation combination
improved the IC50s of NVP 3444.6 ± 834.5, 1132.6 ± 180.4,
and 100.6 ±32.5f o l d s ,r e s p e c t i v e l y( Table 2).
T h eC o m p l e t eS e to fD i ﬀe r e n c e sf r o mC o n s e n s u sB .The dif-
ferences from consensus B were listed in Table 3, and these
additional mutations might aﬀect susceptibility.
4. Discussion
H221Y was ﬁrst reported related to NRTI treatment in 2003
[9], but in recent study, H221Y was concerned associated
with exposed to NNRTIs [6, 10]. Ceccherini-Silberstein et al.
found the prevalence rate of H221Y in isolates from patients
failing NVP treatment was 10.3% and the mutation was
includedinthetop10and15determinantsforNVPandEFV
resistance, respectively, ranking even above some classical
NNRTI resistance mutations, such as K101E, V108I, and
G190E [6]. The group found H221Y was strongly associated
with the use of NVP and showed positive interactions
with Y181C and was also negatively associated with the
use of ZDV and with TAMs (particularly TAMs-2, such as
D67N, K70R, K219Q/E, and T215F) and was then associated
with an increased susceptibility to ZDV. When H221Y was
copresent with TAMs-2, the ZDV susceptibility was even
greater than that observed when TAMs-2 were copresent
with Y181C. The presence of H221Y along with Y181C was
associated with a 12.4-fold increase in NVP resistance. Jiang
et al. found that the occurrence of the H221Y was 19.8%
in 91 patients receiving nevirapine and lamivudine plus
stavudine (57.1%) or zidovudine (42.9%) [10]. Reuman et
al. analyzed viruses from 13039 individuals with sequences
containing at least one of 52 published NNRTI-selected
mutations; the frequency of H221Y among 1510 viruses
from individuals who received nevirapine but no other
NNRTI was 12%. H221Y occurred along with Y181C in
our study (data not shown) and the virus with mutation
pattern K103N/Y181C/H221Y can replicate stably in vitro
without drug pressure [8]. Our study showed that as for
themutationproﬁlesK101Q/Y181C,K101Q,V179D/Y181C,
V179D, K103N/Y181C, and K103N, the presence of H221Y,
respectively lead to 2.2 ± 0.9, 3.2 ± 0.3, 3.6 ± 0.5, 3.0 ± 0.4,
2.1 ±0.5, and 2.2 ±0.1-fold increase in NVP resistance.
Y181CisaveryimportantNNRTIs-relateddrugresistant
mutation, and the mutation can cause high-level resistance
to NVP and DLV and low-level resistance to EFV; otherwise,
this mutation can increase susceptibility to AZT and TDF.6 AIDS Research and Treatment
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Figure 3: The curves of percent inhibition of virus 103N-1∼103N-4, Con-1 to log10 NVP concentration.
SungkanuparphgroupreportedtheprevalencerateofY181C
was 59.5% among the 158 NNRTI failure patients (for a
median NNRTI treatment period of 88 weeks) [11]. Taiwo et
al. found the frequency of Y181C was 42.9% in the patients
receiving NNRTI treatment for a median period of 53 weeks
[12]. Y181C presents in 40% of patients failing NVP and
has the third-greatest weight in the SVR (support vector
regression)modelforNVPresistance[6].InReumangroup’s
study [13], Y181C is the most common resistant mutation
among the sequences from patients receiving NVP (48%),
and nearly 17% (n = 2233) sequences contained three
or more NNRTIs-resistant mutations and these NNRTIs-
resistant proﬁles often carried Y181C and occurred with one
or more thymidine analogue mutations, which suggested
these mutation pattern might signiﬁcantly associated with
the function of HIV-1 RT. Many studies have reported
the phenotype resistance of Y181C, Bacheler et al. [14]
found the virus with K103N/Y181C and other mutations
conferring above 1600-fold resistance to NVP, and Qari et
al. [15] covered the virus containing K101E/Y181C/G190AAIDS Research and Treatment 7
and other mutations could increase 893-fold resistance to
NVP. As we have known [16], Y181C copresent with TAMs2
could increase the susceptibility to ZDV. In our study,
mutation patterns K101Q/H221Y, K101Q, V179D/H221Y,
V179D, K103N/H221Y, and K103N, Y181C could, respec-
tively, improve 759.1 ± 41.9, 1297.0 ± 289.1, 390.0 ± 101.6,
312.5±45.3,41.9±8.4,and47.9±4.2-foldtoNVPresistance.
Although H221Y mutation alone just increases 2.1 ∼ 3.6-
fold resistance to NVP, the mutation could improve 100.6 ∼
3444.6-foldresistancetoNVPwhenitcopresentwithY181C.
To be speciﬁc, to K101Q, V179D, and K103N, Y181C/H221Y
couldconfer3444.6±834.5,1132.6±180.4,and100.6±32.5-
fold resistance to NVP.
Ceccherini-Silberstein et al. [6] described the resistant
characters of 9 novel NNRTI-related mutations including
K101Q, I135M/T, H221Y, K223E/Q, L228H/R, and V179I. In
these novel mutations, K101Q and I135T copresented with
K103N which related to the increase resistance of EFV and
NVP. Residue 101 may establish hydrogen bonds with EFV
and may directly interact with correlated residue 102 by van
der Waals interaction. In previous study, the appearance of
K101Q might be based on the occurrence of K103N [17].
In other study [18], residue 101 showed negative association
with HLA-A2 genotype which suggested, in the presence of
HLA-A2 restricted immune response, position 101 may be
under negative selective pressure that favors the preservation
of the wild-type amino acid. As for residue 179, only V179F
mutation did not decrease the susceptibility to etravirine;
however,whenthemutationcombinedwithY181C,theviral
etravirine susceptibility could be reduced more than 100-
fold[19–22].ThusreceivingNNRTIstreatmentonlongterm
might result in the accumulation of accessory mutations and
lead to higher level of drug resistance.
With the upcoming approval of the new NNRTIs, under-
standing the eﬃcacy of these NNRTIs mutation proﬁles
shows more and more importance. Further in vitro and
clinical studies are therefore necessary to conﬁrm the eﬃcacy
of these new mutation patterns. These studies will provide
information for deeper understanding of the mechanisms of
drug resistance.
5. Conclusions
The success of HAART (Highly Active Antiretroviral Ther-
apy) in treating AIDS patients is hampered by the emergence
of drug-resistant strains, and more and more studies indicate
that there are more drug-resistant mutations than we have
known. The roles of these novel mutations in drug resistance
have still been indistinct. In this study, we found that
Y181C remarkably improved the IC50 to NVP, although the
novel mutation H221Y only slightly conferred resistance to
NVP, when it combined with Y181C, the phenotypic drug
resistance folds were improved extremely.
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